Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 15/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 13/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 10/20 | 0.39 |
| ▸ | TSHR | P16473 | 9/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 8/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 11/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 10/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14524120 | 0.95 | HRH3 (0.36) | CYP2D6CYP3A4CYP1A2TSHRCYP2C19 | |
| SCHEMBL10111444 | 0.93 | CYP2D6 (0.39) | CYP2D6CYP3A4CYP1A2TSHRCYP2C19 | |
| SCHEMBL24789561 | 0.91 | HRH3 (0.35) | CYP2D6CYP3A4CYP1A2TSHRCYP2C19 | |
| SCHEMBL10111441 | 0.91 | CYP2D6 (0.39) | CYP2D6CYP3A4CYP1A2TSHRCYP2C19 | |
| SCHEMBL12911788 | 0.88 | CYP2D6 (0.39) | CYP2D6CYP3A4CYP1A2TSHRCYP2C19 | |
| SCHEMBL12758830 | 0.88 | CYP2D6 (0.35) | CYP2D6CYP3A4CYP1A2TSHRCYP2C19 | |
| SCHEMBL9963381 | 0.88 | CYP2D6 (0.39) | CYP2D6CYP3A4CYP1A2TSHRCYP2C19 | |
| SCHEMBL10168682 | 0.88 | USP2 (0.39) | CYP2D6CYP3A4CYP1A2TSHRCYP2C19 | |
| SCHEMBL17658849 | 0.88 | CYP2D6 (0.35) | CYP2D6CYP3A4CYP1A2TSHRCYP2C19 | |
| SCHEMBL10255913 | 0.88 | CYP2D6 (0.35) | CYP2D6CYP3A4CYP1A2TSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066029-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2024-02-29 | — | — | US | disclosed |
| WO-2023244918-A1 | QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. (US) | 2023-12-21 | — | — | WO | disclosed |
| WO-2023071973-A1 | FUSED BICYCLIC COMPOUND FOR INHIBITING ACTIVITY OF TYROSINE KINASE | SHENZHEN TARGETRX, INC. (CN) | 2023-05-04 | — | — | WO | disclosed |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20210186959-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2021-06-24 | — | — | US | disclosed |
| EP-3492471-B1 | FUSED BICYCLIC COMPOUND FOR INHIBITING ACTIVITY OF TYROSINE KINASE | SHENZHEN TARGETRX INC (CN) | 2020-12-02 | — | — | EP | disclosed |
| US-20190201380-A1 | SPIROCYCLIC COMPOUNDS | KALYRA PHARMACEUTICALS, INC. | 2019-07-04 | — | — | US | disclosed |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2019-06-27 | — | — | US | disclosed |
| US-20190183886-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2019-06-20 | — | — | US | disclosed |
| EP-3492471-A1 | FUSED BICYCLIC COMPOUND FOR INHIBITING ACTIVITY OF TYROSINE KINASE | Shenzhen Targetrx, Inc. (CN) | 2019-06-05 | — | — | EP | disclosed |
| US-20180133200-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
| US-20180133200-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
| US-9493474-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2016-11-15 | — | — | US | disclosed |
| US-20140288042-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME LLC | 2014-09-25 | — | — | US | disclosed |
| US-20120010186-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2012-01-12 | — | — | US | disclosed |
| US-7229996-B2 | Rifamycin derivatives | CUMBRE PHARMACEUTICALS INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-7202246-B2 | Spiro-rifamycin derivatives targeting RNA polymerase | CUMBRE PHARMACEUTICALS INC. (US) | 2007-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SCN2A, HTR2A, HTR2C | CYP2D6 571/4885CYP3A4 1177/4885CYP1A2 201/4885 |
| US-20140288042-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | KCNJ2, KCNJ11, KCNK2 | CYP2D6 2792/4885CYP3A4 4541/4885CYP1A2 2417/4885 |
| US-20190201380-A1 | SPIROCYCLIC COMPOUNDS | PKD1, AR, PKD2 | CYP2D6 865/4885CYP3A4 1636/4885CYP1A2 1217/4885 |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SCN2A, HTR2A, HTR2C | CYP2D6 571/4885CYP3A4 1177/4885CYP1A2 201/4885 |
| US-20120010186-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | SCD, SCD5, FASN | CYP2D6 942/4885CYP3A4 828/4885CYP1A2 619/4885 |
| US-20180133200-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | CYP2D6 3706/4885CYP3A4 3158/4885CYP1A2 3812/4885 |
| US-20190183886-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | CYP2D6 3706/4885CYP3A4 3158/4885CYP1A2 3812/4885 |
| US-20210186959-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | CYP2D6 3706/4885CYP3A4 3158/4885CYP1A2 3812/4885 |
| US-20240066029-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | CYP2D6 3706/4885CYP3A4 3158/4885CYP1A2 3812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.